Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.031
Sell
RSI(14)
32.154
Neutral
STOCH(KDJ)(9,3,3)
44.204
Sell
ATR(14)
1.537
High Vlolatility
CCI(14)
-91.841
Neutral
Williams %R
92.956
Oversold
TRIX(12,20)
-0.815
Sell
StochRSI(14)
0.000
Sell
Omnicell Inc
OMCL32.750USD
-2.450-6.96%
Close 03/27, 16:00（ET）Quotes delayed by 15 min
1.10BMarket Cap
733.65P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Omnicell Inc
Currency: USD Updated: 2026-03-27Key Insights
Omnicell Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 44 out of 208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 57.43.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Omnicell Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Omnicell Inc Highlights
StrengthsRisks
Omnicell, Inc. is a provider of medication management solutions and adherence tools for health systems and pharmacies. The Company is focused on transforming pharmacy care through outcomes-centric innovation designed to optimize clinical and business outcomes across all settings of care through a portfolio of robotics, smart devices, intelligent software, and services. Its point of care automation solutions is designed to improve clinician workflows in patient care areas of the healthcare system, such as nursing units, patient wards, operating rooms, and emergency departments. The Company’s XT Series automated dispensing systems for medications and supplies, which are used in nursing units and other clinical areas of the hospital, are designed to support workflows specific to each area of the hospital, with various software and hardware options. For the operating room, the Company also offer specialized automated dispensing systems.
Overvalued
The company’s latest PE is 733.65, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 46.33M shares, decreasing 19.34% quarter-over-quarter.
Held by Keeley-Teton Advisors, LLC
Star Investor Keeley-Teton Advisors, LLC holds 25.80K shares of this stock.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
57.429
Target Price
+63.15%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-03-27The current financial score of Omnicell Inc is 6.35, ranking 154 out of 208 in the Healthcare Equipment & Supplies industry. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 313.98M, representing a year-over-year increase of 2.32%, while its net profit experienced a year-over-year increase of 112.79%.
Score
Financials
7.88
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
2.45
Operational Efficiency
7.37
Growth Potential
6.90
Shareholder Returns
7.14
Omnicell Inc's Company Valuation
Currency: USD Updated: 2026-03-27The current valuation score of Omnicell Inc is 7.55, ranking 75 out of 208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is 733.65, which is 29.01% below the recent high of 946.46 and 126.37% above the recent low of -193.44.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 44/208
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-03-27The current earnings forecast score of Omnicell Inc is 8.00, ranking 61 out of 208 in the Healthcare Equipment & Supplies industry. The average price target is 47.00, with a high of 63.00 and a low of 36.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
57.429
Target Price
+63.15%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
92
Total
4
Median
7
Average
Company name
Ratings
Analysts
Omnicell Inc
OMCL
8
Boston Scientific Corp
BSX
37
Intuitive Surgical Inc
ISRG
36
Edwards Lifesciences Corp
EW
35
Veeva Systems Inc
VEEV
33
Thermo Fisher Scientific Inc
TMO
29
1
2
3
...
19
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-03-27The current price momentum score of Omnicell Inc is 6.54, ranking 108 out of 208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 39.39 and the support level at 29.15, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
34.332
Sell
MA10
34.156
Sell
MA20
36.724
Sell
MA50
40.932
Sell
MA100
41.252
Sell
MA200
35.869
Sell
Institutional Confidence
Currency: USD Updated: 2026-03-27The current institutional shareholding score of Omnicell Inc is 10.00, ranking 1 out of 208 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 103.23%, representing a quarter-over-quarter decrease of 4.97%. The largest institutional shareholder is The Vanguard, holding a total of 5.53M shares, representing 12.18% of shares outstanding, with 2.52% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
Dimensional Fund Advisors, L.P.
Wellington Management Company, LLP
State Street Investment Management (US)
Millennium Management LLC
Lazard Asset Management, L.L.C.
Amova Asset Management Co., Ltd.
Nomura Investment Management Business Trust
Cadian Capital Management LP
1
2
Risk Assessment
Currency: USD Updated: 2026-03-27The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Omnicell Inc is 6.98, ranking 47 out of 208 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.83. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.83
VaR
+4.05%
240-Day Maximum Drawdown
+36.27%
240-Day Volatility
+60.22%
Return
Best Daily Return
60 days
+6.85%
120 days
+13.56%
5 years
+33.00%
Worst Daily Return
60 days
-16.30%
120 days
-16.30%
5 years
-34.52%
Sharpe Ratio
60 days
-2.31
120 days
+0.62
5 years
-0.37
Risk Assessment
Maximum Drawdown
240 days
+36.27%
3 years
+67.57%
5 years
+86.59%
Return-to-Drawdown Ratio
240 days
+0.14
3 years
-0.27
5 years
-0.18
Skewness
240 days
-0.82
3 years
+2.22
5 years
+0.55
Volatility
Realised Volatility
240 days
+60.22%
5 years
+51.05%
Standardised True Range
240 days
+4.17%
5 years
+7.59%
Downside Risk-Adjusted Return
120 days
+81.44%
240 days
+81.44%
Maximum Daily Upside Volatility
60 days
+44.36%
Maximum Daily Downside Volatility
60 days
+51.71%
Liquidity
Average Turnover Rate
60 days
+1.13%
120 days
+1.33%
5 years
--
Turnover Deviation
20 days
-1.37%
60 days
-8.15%
120 days
+8.09%
Peer Comparison
Healthcare Equipment & Supplies
Omnicell Inc
OMCL
7.33 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Thermo Fisher Scientific Inc
TMO
8.39 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Bioventus Inc
BVS
8.28 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Anika Therapeutics Inc
ANIK
8.13 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
LNTH
8.07 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Edwards Lifesciences Corp
EW
8.05 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
